Indication intelligence, analysis and sector perception

Applied Genetic Technologies (AGTC) prices public offering of 16,66 M shares at $0.60

July 13, 2022 8:09am

Trading -$0.45 or -52.67% to $0.40 in the a.m.

Closed down -$0.011 to $0.847 with an aftermarket of -$0.26 or -30.38% to $0.59

What a JOKE, actually a travesty for investors!

Underwriter – HC Wainwright & Co.

Draft prospectus … https://ir.agtc.com/node/11796/html

https://ir.agtc.com/node/11796/html#suptx378148_7

The Bottom Line: As of May 31, 2022, we had cash and cash equivalents totaling $51.9 million – WHT couldn’t they WAIT?

On-going concern?

Under a Nasdaq $1.00 listing pricing, going to the OTCQB?

WHO in management made this decision, CEO Washer and CFO Lieber should be relieved of duty?

Stupidest move in this market!

Also, with this level of warrants -- 2.5 M and underwriter 30-day option to purchase additional 2.5 M shares - should SCARE investors!

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.